Molecular mechanisms underlying hepatoprotective activity of lutein in the context of intestinal failure-associated liver disease

IF 9.1 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Izabela Żółnowska , Aleksandra Gostyńska-Stawna , Maciej Stawny
{"title":"Molecular mechanisms underlying hepatoprotective activity of lutein in the context of intestinal failure-associated liver disease","authors":"Izabela Żółnowska ,&nbsp;Aleksandra Gostyńska-Stawna ,&nbsp;Maciej Stawny","doi":"10.1016/j.phrs.2024.107421","DOIUrl":null,"url":null,"abstract":"<div><p>Intestinal failure-associated liver disease (IFALD) is a spectrum of liver diseases occurring in patients not exposed to liver-damaging factors other than those linked to intestinal dysfunction. The pathogenesis of this disease is multifactorial. It is estimated that up to 90 % of people taking long-term parenteral nutrition may develop IFALD, with particular risk for premature neonates and infants due to their immature antioxidant protection and bile acid metabolism. The lack of effective prevention and treatment methods for IFALD encourages scientists to search for new therapeutic solutions. The use of lutein as a substance with antioxidant and anti-inflammatory effects seems to be of great potential in such indication, especially since patients on parenteral nutrition are at risk of deficits in various plant-based nutrients, including lutein. In this review, we explain the pathogenesis of IFALD and summarize knowledge of the hepatoprotective properties of lutein, underscoring its potential as a treatment option. The hepatoprotective effects of lutein and their proposed mechanisms of action are supported by studies on cells and animals exposed to various liver-damaging factors, such as lipopolysaccharide, high-fat diet, alcohol, and more. Finally, we provide perspectives on the future application of lutein in therapy.</p></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"209 ","pages":"Article 107421"},"PeriodicalIF":9.1000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1043661824003669/pdfft?md5=92dde2611e7fee5d8ed114874628986c&pid=1-s2.0-S1043661824003669-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661824003669","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Intestinal failure-associated liver disease (IFALD) is a spectrum of liver diseases occurring in patients not exposed to liver-damaging factors other than those linked to intestinal dysfunction. The pathogenesis of this disease is multifactorial. It is estimated that up to 90 % of people taking long-term parenteral nutrition may develop IFALD, with particular risk for premature neonates and infants due to their immature antioxidant protection and bile acid metabolism. The lack of effective prevention and treatment methods for IFALD encourages scientists to search for new therapeutic solutions. The use of lutein as a substance with antioxidant and anti-inflammatory effects seems to be of great potential in such indication, especially since patients on parenteral nutrition are at risk of deficits in various plant-based nutrients, including lutein. In this review, we explain the pathogenesis of IFALD and summarize knowledge of the hepatoprotective properties of lutein, underscoring its potential as a treatment option. The hepatoprotective effects of lutein and their proposed mechanisms of action are supported by studies on cells and animals exposed to various liver-damaging factors, such as lipopolysaccharide, high-fat diet, alcohol, and more. Finally, we provide perspectives on the future application of lutein in therapy.

肠功能衰竭相关肝病中叶黄素保肝活性的分子机制
肠功能衰竭相关性肝病(IFALD)是一种肝脏疾病,发生在未暴露于除与肠功能障碍有关的因素之外的其他肝脏损伤因素的患者身上。这种疾病的发病机制是多因素的。据估计,多达 90% 的长期肠外营养患者可能会患上 IFALD,早产新生儿和婴儿由于抗氧化保护和胆汁酸代谢功能尚未成熟,患上 IFALD 的风险尤其高。IFALD 缺乏有效的预防和治疗方法,这促使科学家们寻找新的治疗方案。叶黄素作为一种具有抗氧化和抗炎作用的物质,似乎在此类适应症中具有很大的潜力,特别是因为接受肠外营养的患者有可能缺乏包括叶黄素在内的各种植物营养素。在这篇综述中,我们解释了 IFALD 的发病机制,并总结了叶黄素的保肝特性,强调了叶黄素作为一种治疗选择的潜力。叶黄素的保肝作用及其拟议的作用机制得到了暴露于各种肝损伤因素(如脂多糖、高脂饮食、酒精等)的细胞和动物的研究的支持。最后,我们对叶黄素未来在治疗中的应用进行了展望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信